About Comparative Biosciences, Inc.
Comparative Biosciences was founded in 1996 to provide expert scientific resources and quality service to all sectors of the biomedical and biopharmaceutical community. We offer extensive experience in GLP and non-GLP preclinical toxicology, efficacy, pharmacology, pharmacokinetics-pharmacodynamics, histopathology and safety studies on all laboratory species.
Our particular areas of expertise include ocular, dermatology, fibrosis, otic/ototoxicity, wound healing, burns, stem cells, oncology, renal, ophthalmology, inflammation, immune-mediated models cardiovascular and pulmonary studies, infection models and devices, as well as contract histopathology, immunohistochemistry and custom model development.
CBI is the industry leader in conducting difficult and uniqueIND-enabling research studies including those involving stem cells, stem cell and device combinations, delivery systems,
diabetes and cancer therapies.
We have a fully staffed, state-of-the-art, AAALAC-accredited facility that is purpose-built with both an in-house histopathology laboratory and a full-time quality assurance unit. We are registered with the FDA, USDA and OLAW, and our clients range from small biomedical companies to pharmaceutical giants, academia, defense and government.
History
CBI was founded in 1996 by Carol Meschter, DVM, PhD, DACVP, Dr. Steve Adams, DVM, PhD, DACLAM, and Tom Duffy, CPA, in Santa Clara, Calif. Since our founding, we have steadily increased and expanded our capabilities and areas of expertise. In 2004, we moved into our new state-of-the-art, purpose-built facilities in Sunnyvale, Calif.
Learn more about our core management team and scientific advisers.